Michelle Lock is Relief’s Interim Chief Executive Officer and a member of Relief’s Board of Directors. She has nearly 30 years of biopharmaceutical strategic, operational and commercialization experience.

Paolo Galfetti is Chief Operating Officer. He has over 20 years of management experience in the pharmaceutical sector, including in the areas of business development and licensing, operational strategic management, clinical research, and pharmaceutical discovery and development. 

Jeremy Meinen serves as chief financial officer and treasurer. Prior to joining Relief, Jeremy provided financial consulting and controlling services to companies in various industries. Jeremy is a Swiss certified public accountant.

Marco Marotta serves as Chief Business Officer. He brings deep, international expertise in operations, sales and business development within the pharmaceutical sector.

Christopher Wick is Relief Therapeutics’ U.S. Country Lead and is responsible for leading company’s U.S. commercial and sales teams. Prior to joining Relief, Christopher held positions in sales of increasing responsibility at Alexion Pharmaceuticals, Inc., GlaxoSmithKline and Novartis. where he developed and led high-performing, excellence award-winning teams and achieved best-in-the-nation sales for two rare disease products and consistently received top sales rankings.

Drew serves as Executive Director and Head of U.S. Marketing. She is proven leader, with a successful track record of launching numerous products in the rare disease space, and has deep expertise in digital technology, strategic planning and team building.

Raghuram (Ram) Selvaraju, Ph.D., MBA, is a Managing Director and Senior Healthcare Analyst in the Equity Research Division of H.C. Wainwright & Co., a New York-based full-service investment bank heavily focused on the healthcare sector. He has over 15 years of experience on Wall Street and previously was a pharmaceutical researcher at Serono in Switzerland. He holds Ph.D. and M.S. degrees from the University of Geneva and an M.B.A. from Cornell University.

Tom Plitz recently served as Chief Executive Officer of Chord Therapeutics SA, a privately held biopharmaceutical firm based in Geneva, Switzerland, which was acquired by Merck KGaA in January 2022. He has more than two decades of R&D experience from senior management positions in the pharmaceutical industry.

Patrice Jean is the Chair of the Life Sciences Practice at Hughes Hubbard & Reed, an international law firm based in New York City. She has over a decade of experience counselling leading and startup pharmaceutical, chemical and biotechnology companies in all areas of patent law, including asserting and defending patent rights underlying core technologies and innovations.

Michelle Lock is the Chief Operating Officer of Covis Pharma Group, a global specialty pharmaceutical company based in Zug, Switzerland. She has nearly 30 years of biopharmaceutical strategic, operational and commercialization experience.